Legend Biotech’s stock has experienced a significant decline of approximately 69.8% over the past three years, raising concerns among investors about whether its current low price reflects existing challenges. Despite the weak share performance, the company appears undervalued based on valuation metrics, particularly with a price-to-sales (P/S) ratio of 3.2x, which is substantially below the industry average of 13.1x. Analysts suggest that future revenue growth from its cell therapy pipeline could support the stock’s value, although risks related to clinical execution and funding needs persist. The key issue remains whether the current stock price adequately compensates investors for these risks, or if it presents a buying opportunity amid concerns about the company’s long-term performance.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/markets/stocks/articles/legend-biotech-legn-stock-may-151009914.html
